Who Exports Pembrolizumab from India — 34 Suppliers Behind a $1.9M Market
India's pembrolizumab export market is supplied by 34 active exporters who collectively shipped $1.9M across 215 shipments. GNH INDIA PHARMACEUTICALS LIMITED leads with a 14.8% market share, followed by GEMINI HEALTHWORLD LLP and 3S PHARMACEUTICALS INDIA PRIVATE LIMITED. The top 5 suppliers together control 54.6% of total export value, reflecting a moderately competitive market structure.
Top Pembrolizumab Exporters from India — Ranked by Export Value
GNH INDIA PHARMACEUTICALS LIMITED is the leading pembrolizumab exporter from India, holding a 14.8% share of the $1.9M market across 215 shipments from 34 exporters. The top 5 suppliers — GNH INDIA PHARMACEUTICALS LIMITED, GEMINI HEALTHWORLD LLP, 3S PHARMACEUTICALS INDIA PRIVATE LIMITED, VAMA LIFECARE PRIVATE LIMITED, SHREE KRISHNA LIFECARE — collectively control 54.6% of total export value, indicating a moderately concentrated market. Individual shares are: GNH INDIA PHARMACEUTICALS LIMITED (14.8%), GEMINI HEALTHWORLD LLP (11.0%), 3S PHARMACEUTICALS INDIA PRIVATE LIMITED (10.4%), VAMA LIFECARE PRIVATE LIMITED (9.4%), SHREE KRISHNA LIFECARE (9.0%).
Top Pembrolizumab Exporters from India
Ranked by export value · 34 active suppliers · Indian Customs (DGFT) data
| # | Supplier & Formulations | Value | Ctry. | Share |
|---|---|---|---|---|
| 1 | GNH INDIA PHARMACEUTICALS LIMITED PEMBROLIZUMAB/100MG/4ML VLSKEYTRUDA 100MG/4ML PEMBROLIZUMAB/100MG/4PEMBROLIZUMAB INJECTION 100MG/4ML | $285.3K | 4 | 14.8% |
| 2 | GEMINI HEALTHWORLD LLP HARMLESS MEDICINE FOR HUMAN CONSUMPTION | $212.6K | 1 | 11.0% |
| 3 | 3S PHARMACEUTICALS INDIA PRIVATE LIMITED PEMBROLIZUMAB INJECTION EACH SINGLE VIALHARMLESS MEDICINE FOR HUMAN CONSUMPTIONPEMBROLIZUMAB INJECTION- EACH SINGLE VIA | $201.7K | 2 | 10.4% |
| 4 | VAMA LIFECARE PRIVATE LIMITED HARMLESS MEDICINE FOR HUMAN CONSUMPTION | $181.3K | 1 | 9.4% |
| 5 | SHREE KRISHNA LIFECARE PEMBROLIZUMAB INJECTION 100MG/4MLKEYTRUDA 100MG/4ML VLS | $174.0K | 3 | 9.0% |
| 6 | SPECIALITY MEDICINES PRIVATE LIMITED HARMLESS MEDICINE FOR HUMAN CONSUMPTION | $159.8K | 3 | 8.3% |
| 7 | SPECIALITY MEDICINES LIMITED HARMLESS MEDICINE FOR HUMAN CONSUMPTION | $159.1K | 2 | 8.2% |
| 8 | NU HOSPITALS PRIVATE LIMITED PEMBROLIZUMAB - INJECTIONS - 100MG - KEKEYTRUTA 100MG PEMBROLIZUMAB INJECTIONPEMBROLIZUMAB - INJECTIONS - 100MG - KEY | $130.1K | 1 | 6.7% |
| 9 | G P INTERGLOBE PEMBROLIZUMAB/100MG/4ML VLSKEYTRUDA 100MG/4ML PEMBROLIZUMAB/100MG/4PEMBROLIZUMAB INJECTION 100MG/4ML | $59.9K | 1 | 3.1% |
| 10 | DHEER HEALTHCARE PRIVATE LIMITED HARMLESS MEDICINE FOR HUMAN CONSUMPTION | $48.9K | 1 | 2.5% |
| 11 | K. K. PHARMA SOLUTIONS HARMLESS MEDICINE FOR HUMAN CONSUMPTION | $42.5K | 1 | 2.2% |
| 12 | SPR ONCOCARE PRIVATE LIMITED PEMBROLIZUMAB-KEYTRUDA BATCH Y014413 EXPIRY JUNE 2026 | $26.8K | 2 | 1.4% |
| 13 | ALLEVIARE LIFE SCIENCES PRIVATE LIMITED | $23.9K | 1 | 1.2% |
Related Analysis
Supplier Certification & Compliance Matrix
FDA, WHO-GMP, and EU GMP status for top Pembrolizumab exporters
| Supplier | US FDA | WHO-GMP | EU GMP | ANDAs | Notes |
|---|---|---|---|---|---|
| GNH INDIA PHARMACEUTICALS LIMITED | Not Listed | Yes | No | Not verified | WHO-GDP and ISO 9001:2015 certified pharmaceutical distributor. |
| KWALITY PHARMACEUTICALS LIMITED | Not Listed | Yes | Yes | Not verified | EU GMP approval for Cephalosporin and Oncology manufacturing unit in April 2023. |
| SAVIOUR PHARMACEUTICALS | Not Listed | Yes | Yes | Not verified | Operates WHO-GMP approved plant in Gujarat, India, adhering to global standards. |
TransData Nexus reviewed the regulatory standing of 3 leading Pembrolizumab exporters from India. 0 hold US FDA facility approvals, 3 maintain WHO-GMP certification, and 2 are EU GMP compliant. For regulated markets (US, EU, Australia), prioritise suppliers with active FDA or EU GMP approvals. For semi-regulated markets (Africa, ASEAN, Latin America), WHO-GMP certification is the minimum recommended standard.
Certification status compiled from publicly available regulatory databases including FDA Orange Book, WHO Prequalification database, and EMA GMP registry. Buyers should independently verify compliance status with the relevant regulatory authority before placing orders.
TransData Nexus Research · Mar 2026
Manufacturing Hub Analysis — Vendor Proximity
India's pharmaceutical clusters relevant to Pembrolizumab sourcing
1Hyderabad — Bulk Drug Capital
Hyderabad, often referred to as the "Bulk Drug Capital of India," is a pivotal hub for active pharmaceutical ingredients (APIs) and bulk drug manufacturing. The city hosts over 800 pharmaceutical companies, including major players like Dr. Reddy’s Laboratories and Aurobindo Pharma. The presence of Genome Valley, India's first biotech cluster, underscores Hyderabad's role in biotech and life sciences innovation. This robust infrastructure and talent pool make Hyderabad a significant contributor to the production of complex biologics such as Pembrolizumab.
2Ahmedabad-Vadodara — Formulations Hub
The Ahmedabad-Vadodara corridor in Gujarat is renowned for its expertise in pharmaceutical formulations. Gujarat contributes nearly 28% of India's pharmaceutical production, with companies like Zydus Lifesciences and Cadila Pharmaceuticals headquartered in the region. The state's mature pharma ecosystem, supported by strong infrastructure and regulatory compliance, positions it as a leader in the formulation and export of finished pharmaceutical products, including monoclonal antibodies like Pembrolizumab.
3Mumbai-Thane-Raigad — Export Gateway
The Mumbai-Thane-Raigad belt serves as a critical export gateway for India's pharmaceutical industry. Mumbai, being a major port city, facilitates the export of pharmaceutical products to global markets. The region's well-established logistics and proximity to international shipping routes enhance its role in the distribution of high-value biologics such as Pembrolizumab. Additionally, the presence of numerous pharmaceutical companies and contract research organizations in this area supports a robust supply chain for both domestic and international markets.
4Baddi-Nalagarh — Tax Incentive Zone
Baddi-Nalagarh in Himachal Pradesh has emerged as a prominent pharmaceutical manufacturing hub, largely due to favorable tax incentives and government policies. The region houses over 1,000 pharmaceutical manufacturing units, making it one of the largest pharma clusters in Asia. Companies in Baddi benefit from cost-effective production capabilities, which can be advantageous for the manufacturing of cost-intensive biologics like Pembrolizumab.
5Sourcing Recommendations
- Diversify Supplier Base: Engage with multiple suppliers across different clusters to mitigate risks associated with regional disruptions.
- Evaluate Supplier Capabilities: Assess the technical expertise and regulatory compliance of suppliers, especially for complex biologics like Pembrolizumab.
- Leverage Export Hubs: Utilize the Mumbai-Thane-Raigad region's logistics infrastructure for efficient international distribution.
- Monitor Regulatory Changes: Stay informed about policy shifts in tax incentives and export regulations that may impact sourcing strategies.
By strategically leveraging the strengths of these pharmaceutical clusters, TransData Nexus can optimize its supply chain for Pembrolizumab, ensuring a reliable and efficient flow from production to global markets.
Recent M&A, Collaborations & Capacity Expansions
Industry developments among top Pembrolizumab exporters from India
Vishnu Chemicals Limited — Vishnu Chemicals acquires Jayansree Pharma to enhance specialty chemicals manufacturing
Vishnu Chemicals Limited announced the 100% equity acquisition of Jayansree Pharma Private Limited for a total consideration of INR 51.99 crore. This acquisition aims to bolster Vishnu Chemicals' specialty chemicals manufacturing capabilities, with plans to commence production of strontium carbonate at the acquired plant in Visakhapatnam, Andhra Pradesh. IMPACT: This acquisition is not directly related to Pembrolizumab exports but reflects the ongoing consolidation in the pharmaceutical sector.
Impact: This acquisition is not directly related to Pembrolizumab exports but reflects the ongoing consolidation in the pharmaceutical sector.
SeQuent Scientific Limited — SeQuent Scientific and Viyash Lifesciences merge to form leading animal health venture
SeQuent Scientific Limited and Viyash Lifesciences Private Limited announced a merger to create a platform with leadership in animal pharmaceuticals and expanded capabilities across the global pharmaceutical market. The merger is expected to enhance the combined entity's scale, deepen research and development capabilities, and strengthen its supply chain. IMPACT: This merger focuses on the animal health sector and does not impact Pembrolizumab exports.
Impact: This merger focuses on the animal health sector and does not impact Pembrolizumab exports.
Zydus Lifesciences Limited — Zydus Lifesciences acquires 50% stake in Sterling Biotech for biotech expansion
Zydus Lifesciences Limited, through its wholly owned subsidiary, acquired a 50% equity stake in Sterling Biotech Limited. Sterling Biotech specializes in gelatin, di-calcium phosphate, and select active pharmaceutical ingredients. This acquisition marks Zydus's foray into specialized biotech products for health and nutrition, catering to consumers preferring animal-free protein or those with lactose intolerance. IMPACT: This acquisition does not directly affect Pembrolizumab exports but indicates Zydus's strategic expansion into biotech products.
Impact: This acquisition does not directly affect Pembrolizumab exports but indicates Zydus's strategic expansion into biotech products.
Common Questions — Pembrolizumab Suppliers from India
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
Q Which pembrolizumab supplier from India is the most reliable for bulk orders?
Based on shipment frequency and export consistency, GNH INDIA PHARMACEUTICALS LIMITED leads with 6 recorded shipments worth $285.3K. GEMINI HEALTHWORLD LLP (26 shipments) and 3S PHARMACEUTICALS INDIA PRIVATE LIMITED (12 shipments) are also established high-volume exporters.
Q How many pembrolizumab manufacturers are there in India?
India has 34 active pembrolizumab exporters with a combined export market of $1.9M across 215 shipments to 21 countries. The top 5 suppliers hold 54.6% of total export value.
Q What certifications should I verify?
Verify: WHO-GMP certification (most markets), US FDA approval (United States), EU GMP certificate (EU/EEA), and Free Sale Certificate from CDSCO. Always request a Certificate of Analysis (CoA) and Certificate of Origin (CoO).
Q What is the typical price range for pembrolizumab from India?
Average FOB unit price: $1743.00 per unit, ranging from $0.72 to $4672.86. Average shipment value: $9.0K.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Supplier Ranking: 34 verified Indian exporters of Pembrolizumab ranked by capped export value from DGFT shipping bill records.
- 2.Export Value Analysis: Total export value aggregated from 215 individual shipping bill records. Values are FOB in USD.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
- 4.Market Concentration: Supplier market share and geographic reach analyzed across 21 destination countries.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
215 Verified Shipments
34 exporters tracked
Expert-Reviewed
By pharmaceutical trade specialists